[SCHEDULE 13G/A] MESA LABORATORIES INC /CO/ SEC Filing

Rhea-AI Filing Summary

BlackRock, Inc. reports beneficial ownership of 378,897 shares of Mesa Laboratories, Inc. (MLAB), representing 6.9% of the outstanding common stock. The filing (Schedule 13G, Amendment No. 10) shows BlackRock has sole voting power for 373,374 shares and sole dispositive power for 378,897 shares. The form states these holdings are held in the ordinary course of business and not for the purpose of changing or influencing control. The issuer's principal executive office is listed at 12100 W 6th Ave, Lakewood, CO. The document includes a certification signed by Spencer Fleming, Managing Director, dated 10/02/2025.

Positive

• Beneficial ownership of 378,897 shares equals 6.9% of Mesa Laboratories common stock
• Sole voting power for 373,374 shares, indicating control over voting of most held shares

Negative

• None.

Insights

Regulatory Compliance Analyst

BlackRock discloses a 6.9% beneficial stake in MLAB with substantial sole voting power.

Itemized ownership shows 378,897 shares beneficially owned and 373,374 shares for which BlackRock holds sole voting power. The filing is a Schedule 13G (Amendment No. 10), indicating passive disclosure under the Exchange Act rules rather than an active solicitation.

The certification explicitly states the shares are held in the ordinary course of business and not to influence control; this language is required to qualify for Schedule 13G treatment.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 10)

MESA LABORATORIES INC

(Name of Issuer)

Common Stock

(Title of Class of Securities)

59064R109

(CUSIP Number)

09/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 59064R109

1

Names of Reporting Persons

BlackRock, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 373,374.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 378,897.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

378,897.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.9 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: MESA LABORATORIES INC
(b)	Address of issuer's principal executive offices: 12100 W 6TH AVE Lakewood CO 80228
Item 2.
(a)	Name of person filing: BlackRock, Inc. In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the "Reporting Business Units") of BlackRock, Inc. and its subsidiaries and affiliates. It does not include securities, if any, beneficially owned by other business units whose beneficial ownership of securities are disaggregated from that of the Reporting Business Units in accordance with such release.
(b)	Address or principal business office or, if none, residence: BlackRock, Inc., 50 Hudson Yards New York, NY 10001
(c)	Citizenship: See Item 4 of Cover Page
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 59064R109
Item 4.	Ownership
(a)	Amount beneficially owned: 378897
(b)	Percent of class: 6.9 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 373374
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 378897
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of MESA LABORATORIES INC. No one person's interest in the common stock of MESA LABORATORIES INC is more than five percent of the total outstanding common shares.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Exhibit 99
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BlackRock, Inc.

Signature:	Spencer Fleming
Name/Title:	Managing Director
Date:	10/02/2025

Exhibit Information

Exhibit 24: Power of Attorney Exhibit 99: Item 7

FAQ

What stake does BlackRock report in Mesa Laboratories (MLAB)?

BlackRock reports beneficial ownership of 378,897 shares, representing 6.9% of MLAB common stock.

How much voting power does BlackRock have in this filing?

The filing shows sole voting power for 373,374 shares and shared voting power of 0 shares.

Was the Schedule 13G filing for passive holdings or an active intent to influence control?

The certification states the securities are held in the ordinary course of business and were not acquired to change or influence control, consistent with Schedule 13G treatment.

When was the Schedule 13G signed and by whom?

The filing is signed by Spencer Fleming, Managing Director, dated 10/02/2025.

Where is Mesa Laboratories' principal executive office listed in the filing?

The issuer's principal executive office is listed as 12100 W 6th Ave, Lakewood, CO 80228.